血液悪性腫瘍検査の世界市場レポート 2025年

血液悪性腫瘍検査市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR13.4％で59億4,000万米ドルに成長します。予測期間における成長の原動力は、個別化がん治療に対する需要の増加、次世代シーケンサーの普及、新興市場におけるヘルスケア支出の増加、プレシジョン・オンコロジー・イニシアチブの拡大、血液がん治療に焦点を当てた臨床試験の増加です。予想される主な動向には、分子検査技術の発展、自動化・高スループット診断プラットフォームの開発、血液悪性腫瘍の進行中の研究と革新、検査解釈における人工知能の統合、血液がんに対するリキッドバイオプシー法の画期的進歩などがあります。

がん診断件数の増加が、今後数年間の血液悪性腫瘍検査市場の成長を牽引すると予想されます。がん診断では、画像検査、臨床検査、生検などのさまざまな医学的検査や評価を通じて、患者のがんの有無、種類、病期を特定します。がん診断の増加は、検診プログラムへのアクセスが改善され、一般市民の意識が高まり、早期発見につながったことに起因しています。血液悪性腫瘍検査は、血液関連がんの早期発見、正確な分類、モニタリングを可能にすることでがんの診断をサポートし、最終的には標的治療の決定を導き、患者の転帰を改善します。例えば、米国の非営利団体である米国がん協会によると、2024年に米国で新たにがんと診断された患者数は200万人を超え、前年比4％増となりました。したがって、がん診断件数の増加が血液悪性腫瘍検査市場の成長を促進しています。

血液悪性腫瘍検査市場の主要企業は、血液がんの早期発見、治療計画、モニタリングを改善する正確でタイムリーな診断ツールを医療従事者に提供するため、迅速分子プロファイリングなどの革新的な診断方法に注力しています。迅速分子プロファイリングは、患者の遺伝子プロファイルを解析して突然変異や変異を特定する診断技術であり、より迅速で個別化された治療方針の決定を可能にします。例えば、2023年11月、米国のがんセンターであるロズウェル・パーク総合がんセンターは、白血病、リンパ腫、多発性骨髄腫などの血液がんをより正確かつ迅速に診断するために設計された次世代遺伝子配列決定ツールであるPanHemeを発表しました。この検査は72時間以内に数百の遺伝子の変異を検出し、診断のスピードと精度を大幅に向上させ、より個別化された治療計画をサポートします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の血液悪性腫瘍検査PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の血液悪性腫瘍検査市場：成長率分析
• 世界の血液悪性腫瘍検査市場の実績：規模と成長、2019年～2024年
• 世界の血液悪性腫瘍検査市場の予測：規模と成長、2024年～2029年、2034年
• 世界の血液悪性腫瘍検査総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の血液悪性腫瘍検査市場：テストタイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 全血球数（CBC）
• フローサイトメトリー
• 分子検査
• 遺伝子検査
• その他テストの種類
• 世界の血液悪性腫瘍検査市場：製品別、実績と予測、2019年～2024年、2024年～2029年、2034年
• キット
• サービス
• 世界の血液悪性腫瘍検査市場：技術別、実績と予測、2019年～2024年、2024年～2029年、2034年
• ポリメラーゼ連鎖反応（PCR）
• 次世代シーケンシング（NGS）
• 免疫組織化学（IHC）
• 細胞遺伝学
• その他の技術
• 世界の血液悪性腫瘍検査市場：治療適応症別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 白血病
• リンパ腫
• 多発性骨髄腫
• 骨髄増殖性腫瘍
• その他の治療適応症
• 世界の血液悪性腫瘍検査市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院
• 診断ラボ
• 学術調査機関
• その他エンドユーザー
• 世界の血液悪性腫瘍検査市場、全血球算定（CBC）のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• ヘモグロビン検査
• ヘマトクリット測定
• 白血球数
• 赤血球数
• 血小板数
• 平均赤血球容積（MCV）
• 平均赤血球ヘモグロビン（MCH）
• 世界の血液悪性腫瘍検査市場、フローサイトメトリーの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 免疫表現型検査
• 細胞周期分析
• アポトーシス検出
• 微小残存病変（MRD）検査
• DNA含有量分析
• 世界の血液悪性腫瘍検査市場、分子検査の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• ポリメラーゼ連鎖反応（PCR）
• 次世代シーケンシング（NGS）
• 逆転写PCR（RT-PCR）
• 蛍光in situハイブリダイゼーション（FISH）
• マイクロアレイ解析
• 世界の血液悪性腫瘍検査市場、遺伝子検査の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 生殖細胞変異検査
• 体細胞変異検査
• 細胞遺伝学的検査
• 染色体異常検出
• 一塩基多型（SNP）解析
• 世界の血液悪性腫瘍検査市場、その他テストタイプのサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 骨髄生検
• 免疫組織化学（IHC）
• 酵素アッセイ
• 血清タンパク質電気泳動（SPEP）
• 画像検査

第7章 地域別・国別分析

• 世界の血液悪性腫瘍検査市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界の血液悪性腫瘍検査市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 血液悪性腫瘍検査市場：競合情勢
• 血液悪性腫瘍検査市場：企業プロファイル
  • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abbott Laboratories
• Novartis Aktiengesellschaft
• GlaxoSmithKline Public Limited Company
• Eli Lilly and Company
• Laboratory Corporation of America Holdings
• Agilent Technologies Inc.
• Sun Pharmaceutical Industries Limited
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• Cipla Limited
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Invitae Corporation
• Adaptive Biotechnologies Corporation
• Invivoscribe Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 血液悪性腫瘍検査市場2029年：新たな機会を提供する国
• 血液悪性腫瘍検査市場2029年：新たな機会を提供するセグメント
• 血液悪性腫瘍検査市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Hematologic malignancies testing involves diagnostic and monitoring procedures aimed at detecting, classifying, and assessing cancers of the blood, bone marrow, and lymphatic system. This testing provides precise identification of the type and subtype of malignancy, helps determine prognosis, informs treatment strategies, and tracks treatment response or disease relapse.

The primary types of tests for hematologic malignancies include complete blood count (CBC), flow cytometry, molecular testing, genetic testing, and other methods. A complete blood count (CBC) measures various blood components such as red blood cells, white blood cells, hemoglobin, hematocrit, and platelets. Products in this area are classified as kits and services. Technologies employed include polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), cytogenetics, among others. These tests address therapeutic indications like leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and more. They are utilized by a range of end-users including hospitals, diagnostic laboratories, academic institutions, research centers, and others.

The hematologic malignancies testing market research report is one of a series of new reports from The Business Research Company that provides hematologic malignancies testing market statistics, including the hematologic malignancies testing industry global market size, regional shares, competitors with the hematologic malignancies testing market share, detailed hematologic malignancies testing market segments, market trends, and opportunities, and any further data you may need to thrive in the hematologic malignancies testing industry. This hematologic malignancies testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hematologic malignancies testing market size has grown rapidly in recent years. It will grow from $3.16 billion in 2024 to $3.59 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth during the historic period can be attributed to an increasing incidence of blood cancers, heightened awareness of early cancer detection, expanded use of flow cytometry and molecular diagnostics, growth in hematology testing across hospitals and laboratories, and improved availability of reimbursement for cancer diagnostic procedures.

The hematologic malignancies testing market size is expected to see rapid growth in the next few years. It will grow to $5.94 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The projected growth in the forecast period is driven by increasing demand for personalized cancer treatments, wider adoption of next-generation sequencing, rising healthcare expenditures in emerging markets, expansion of precision oncology initiatives, and a growing number of clinical trials focused on blood cancer therapies. Key trends expected include advancements in molecular testing technologies, the development of automated and high-throughput diagnostic platforms, ongoing research and innovation in hematologic malignancies, integration of artificial intelligence in test interpretation, and breakthroughs in liquid biopsy methods for blood cancers.

The increasing number of cancer diagnoses is expected to drive the growth of the hematologic malignancies testing market in the coming years. Cancer diagnosis involves identifying the presence, type, and stage of cancer in a patient through various medical tests and evaluations such as imaging, laboratory tests, and biopsies. The rise in cancer diagnoses is attributed to improved access to screening programs and greater public awareness, leading to earlier detection. Hematologic malignancies testing supports cancer diagnosis by enabling early detection, accurate classification, and monitoring of blood-related cancers, which ultimately helps guide targeted treatment decisions and improves patient outcomes. For example, according to the American Cancer Society, a US-based nonprofit organization, over 2 million new cancer cases were diagnosed in the US in 2024, marking a 4% increase from previous years. Therefore, the rising number of cancer diagnoses is driving growth in the hematologic malignancies testing market.

Leading companies in the hematologic malignancies testing market are focusing on innovative diagnostic methods, such as rapid molecular profiling, to provide healthcare professionals with precise and timely diagnostic tools that improve early detection, treatment planning, and monitoring of blood cancers. Rapid molecular profiling is a diagnostic technique that analyzes a patient's genetic profile to identify mutations and variations, allowing for faster and more personalized treatment decisions. For instance, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based cancer center, launched PanHeme, a next-generation gene sequencing tool designed to diagnose hematologic cancers like leukemia, lymphoma, and multiple myeloma with greater accuracy and speed. This test detects mutations in hundreds of genes within 72 hours, significantly enhancing the speed and precision of diagnosis and supporting more personalized treatment plans.

In January 2025, Adaptive Biotechnologies Corporation, a US-based biotechnology firm specializing in hematologic malignancies testing, partnered with NeoGenomics Laboratories, Inc. to expand personalized disease monitoring for blood cancer patients. Through this collaboration, Adaptive Biotechnologies and NeoGenomics aim to broaden access to precise minimal residual disease monitoring in blood cancers by incorporating the clonoSEQ test into NeoGenomics' diagnostic services, thereby improving treatment decisions and disease tracking. NeoGenomics Laboratories Inc. is a US-based public, high-complexity clinical laboratory specializing in cancer genetics diagnostic testing.

Major players in the hematologic malignancies testing market are Johnson & Johnson Private Limited, F. Hoffmann-La Roche Aktiengesellschaft, Merck & Co. Inc., Bayer Aktiengesellschaft, AstraZeneca PLC, Abbott Laboratories, Novartis Aktiengesellschaft, GlaxoSmithKline Public Limited Company, Eli Lilly and Company, Laboratory Corporation of America Holdings, Agilent Technologies Inc., Sun Pharmaceutical Industries Limited, Illumina Inc., Bio-Rad Laboratories Inc., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Invitae Corporation, Adaptive Biotechnologies Corporation, Invivoscribe Inc.

North America was the largest region in the hematologic malignancies testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hematologic malignancies testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hematologic malignancies testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hematologic malignancies testing market consists of revenues earned by entities by providing biopsy testing, cytogenetic testing, and molecular testing (PCR, NGS). The market value includes the value of related goods sold by the service provider or included within the service offering. The hematologic malignancies testing market also includes sales of hematology analyzers, and bone marrow biopsy kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hematologic Malignancies Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hematologic malignancies testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hematologic malignancies testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hematologic malignancies testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Test Type: Complete Blood Count (CBC); Flow Cytometry; Molecular Testing; Genetic Testing; Others Test Type
• 2) By Product: Kits; Services
• 3) By Technology: Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Immunohisto Chemistry (IHC); Cytogenetics; Others Technology
• 4) By Therapeutic Indication: Leukemia; Lymphoma; Multiple Myeloma; Myeloproliferative Neoplasms; Others Therapeutic Indication
• 5) By End User: Hospitals; Diagnostic Labs; Academic and Research Institutions; Others End Users
• Subsegments:
• 1) By Complete Blood Count (CBC): Hemoglobin Testing; Hematocrit Measurement; White Blood Cell Count; Red Blood Cell Count; Platelet Count; Mean Corpuscular Volume (MCV); Mean Corpuscular Hemoglobin (MCH)
• 2) By Flow Cytometry: Immunophenotyping; Cell Cycle Analysis; Apoptosis Detection; Minimal Residual Disease (MRD) Testing; DNA Content Analysis
• 3) By Molecular Testing: Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Reverse Transcriptase-PCR (RT-PCR); Fluorescence In Situ Hybridization (FISH); Microarray Analysis
• 4) By Genetic Testing: Germline Mutation Testing; Somatic Mutation Testing; Cytogenetic Testing; Chromosomal Aberration Detection; Single Nucleotide Polymorphism (SNP) Analysis
• 5) By Others Test Type: Bone Marrow Biopsy; Immunohistochemistry (IHC); Enzyme Assays; Serum Protein Electrophoresis (SPEP); Imaging Tests
• Companies Mentioned: Johnson & Johnson Private Limited; F. Hoffmann-La Roche Aktiengesellschaft; Merck & Co. Inc.; Bayer Aktiengesellschaft; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hematologic Malignancies Testing Market Characteristics

3. Hematologic Malignancies Testing Market Trends And Strategies

4. Hematologic Malignancies Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Hematologic Malignancies Testing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hematologic Malignancies Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hematologic Malignancies Testing Market Growth Rate Analysis
• 5.4. Global Hematologic Malignancies Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hematologic Malignancies Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hematologic Malignancies Testing Total Addressable Market (TAM)

6. Hematologic Malignancies Testing Market Segmentation

• 6.1. Global Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Complete Blood Count (CBC)
• Flow Cytometry
• Molecular Testing
• Genetic Testing
• Others Test Type
• 6.2. Global Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Kits
• Services
• 6.3. Global Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Immunohisto Chemistry (IHC)
• Cytogenetics
• Others Technology
• 6.4. Global Hematologic Malignancies Testing Market, Segmentation By Therapeutic Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Leukemia
• Lymphoma
• Multiple Myeloma
• Myeloproliferative Neoplasms
• Others Therapeutic Indication
• 6.5. Global Hematologic Malignancies Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Labs
• Academic And Research Institutions
• Others End Users
• 6.6. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Complete Blood Count (CBC), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemoglobin Testing
• Hematocrit Measurement
• White Blood Cell Count
• Red Blood Cell Count
• Platelet Count
• Mean Corpuscular Volume (MCV)
• Mean Corpuscular Hemoglobin (MCH)
• 6.7. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Flow Cytometry, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunophenotyping
• Cell Cycle Analysis
• Apoptosis Detection
• Minimal Residual Disease (MRD) Testing
• DNA Content Analysis
• 6.8. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Molecular Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Reverse Transcriptase-PCR (RT-PCR)
• Fluorescence In Situ Hybridization (FISH)
• Microarray Analysis
• 6.9. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Genetic Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Germline Mutation Testing
• Somatic Mutation Testing
• Cytogenetic Testing
• Chromosomal Aberration Detection
• Single Nucleotide Polymorphism (SNP) Analysis
• 6.10. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Others Test Type, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bone Marrow Biopsy
• Immunohistochemistry (IHC)
• Enzyme Assays
• Serum Protein Electrophoresis (SPEP)
• Imaging Tests

7. Hematologic Malignancies Testing Market Regional And Country Analysis

• 7.1. Global Hematologic Malignancies Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hematologic Malignancies Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hematologic Malignancies Testing Market

• 8.1. Asia-Pacific Hematologic Malignancies Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hematologic Malignancies Testing Market

• 9.1. China Hematologic Malignancies Testing Market Overview
• 9.2. China Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hematologic Malignancies Testing Market

• 10.1. India Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hematologic Malignancies Testing Market

• 11.1. Japan Hematologic Malignancies Testing Market Overview
• 11.2. Japan Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hematologic Malignancies Testing Market

• 12.1. Australia Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hematologic Malignancies Testing Market

• 13.1. Indonesia Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hematologic Malignancies Testing Market

• 14.1. South Korea Hematologic Malignancies Testing Market Overview
• 14.2. South Korea Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hematologic Malignancies Testing Market

• 15.1. Western Europe Hematologic Malignancies Testing Market Overview
• 15.2. Western Europe Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hematologic Malignancies Testing Market

• 16.1. UK Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hematologic Malignancies Testing Market

• 17.1. Germany Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hematologic Malignancies Testing Market

• 18.1. France Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hematologic Malignancies Testing Market

• 19.1. Italy Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hematologic Malignancies Testing Market

• 20.1. Spain Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hematologic Malignancies Testing Market

• 21.1. Eastern Europe Hematologic Malignancies Testing Market Overview
• 21.2. Eastern Europe Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hematologic Malignancies Testing Market

• 22.1. Russia Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hematologic Malignancies Testing Market

• 23.1. North America Hematologic Malignancies Testing Market Overview
• 23.2. North America Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hematologic Malignancies Testing Market

• 24.1. USA Hematologic Malignancies Testing Market Overview
• 24.2. USA Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hematologic Malignancies Testing Market

• 25.1. Canada Hematologic Malignancies Testing Market Overview
• 25.2. Canada Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hematologic Malignancies Testing Market

• 26.1. South America Hematologic Malignancies Testing Market Overview
• 26.2. South America Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hematologic Malignancies Testing Market

• 27.1. Brazil Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hematologic Malignancies Testing Market

• 28.1. Middle East Hematologic Malignancies Testing Market Overview
• 28.2. Middle East Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hematologic Malignancies Testing Market

• 29.1. Africa Hematologic Malignancies Testing Market Overview
• 29.2. Africa Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hematologic Malignancies Testing Market Competitive Landscape And Company Profiles

• 30.1. Hematologic Malignancies Testing Market Competitive Landscape
• 30.2. Hematologic Malignancies Testing Market Company Profiles
  • 30.2.1. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Hematologic Malignancies Testing Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Novartis Aktiengesellschaft
• 31.3. GlaxoSmithKline Public Limited Company
• 31.4. Eli Lilly and Company
• 31.5. Laboratory Corporation of America Holdings
• 31.6. Agilent Technologies Inc.
• 31.7. Sun Pharmaceutical Industries Limited
• 31.8. Illumina Inc.
• 31.9. Bio-Rad Laboratories Inc.
• 31.10. Cipla Limited
• 31.11. Hikma Pharmaceuticals PLC
• 31.12. Lupin Limited
• 31.13. Invitae Corporation
• 31.14. Adaptive Biotechnologies Corporation
• 31.15. Invivoscribe Inc.

32. Global Hematologic Malignancies Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hematologic Malignancies Testing Market

34. Recent Developments In The Hematologic Malignancies Testing Market

35. Hematologic Malignancies Testing Market High Potential Countries, Segments and Strategies

• 35.1 Hematologic Malignancies Testing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hematologic Malignancies Testing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hematologic Malignancies Testing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer